National Cancer Institute (NCI) - Recruiting 19 years to 79 years. - A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma.
Eastern Cooperative Oncology Group - Recruiting 18 years or older. - A Randomized, Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence.
Arbeitsgemeinschaft medikamentoese Tumortherapie - Recruiting 18 years to 75 years. - Randomised Phase II Pilot Study: Induction Chemotherapy With Docetaxel, Cisplatin and Cetuximab Versus Docetaxel, Cisplatin and 5 FU Followed by Radiotherapy With Cetuximab for Locally Advanced or Not Resectable Carcinoma of the Head and Neck.
Radiation Therapy Oncology Group - Recruiting 18 years or older. - Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck.
Groupe Oncologie Radiotherapie Tete et Cou - Recruiting 18 years or older. - Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Phase Ib Trial of Concurrent Cetuximab (ERBITUXr) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOYr) in Locally Advanced Head and Neck Cancer.